JPMorgan analyst Eric Joseph upgraded Karyopharm Therapeutics to Overweight from Neutral and doubled his price target for the shares to $16 from $8.

Wedbush analyst David Nierengarten raised his price target for Karyopharm Therapeutics to $11 from $6 after the FDA on Wednesday approved selinexor, now branded as Xpovio.

Shares of Karyopharm are moving sharply lower after the FDA posted briefing documents for the Oncologic Drugs Advisory Committee Meeting planned for February 26 to review the New Drug Application for Selinexor.

Take a look at three trading ideas to prep you for the next trading session.

Grail, a Hong Kong-US oncology diagnostics company, announced a $300 million C financing. The company is sequencing large populations of people -- some with cancer, some without -- to discover an early blood-based diagnostic test for cancer.

Based in Watertown, Massachusetts, Syros Pharmaceuticals is a biopharmaceutical company that is developing treatments to control genes in patients with cancer, immune-mediated diseases, and other illnesses.

Biotech stocks—and the stock market in general—took a dive at the beginning of 2016, headed down on macroeconomic factors such as financial instability in China.

Insider buying decreased last week with insiders buying $36.59 million of stock compared to $38.72 million in the week prior. Selling also declined slightly with insiders selling $1.08 billion of stock last week compared to $1.09 billion in the week prior.

Recent small cap picks.

One of the biggest events in healthcare annually, the American Society of Hematology’s annual meeting (56th!) begins on December 6, but abstracts from the conference will be released this morning. Here's a primer on the stocks to watch.